Qiagen, Abbott Enter into Molecular Dx Pact | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Qiagen and Abbott late on Tuesday announced a broad molecular diagnostics agreement covering HIV, human papillomavirus, and hepatitis C.

Under the terms of the deal, Qiagen will receive kits from Abbott for a PCR-based molecular assay for HIV-1 viral load testing in the US and Canada. In return, it will provide Abbott certain key products needed for a PCR-based HPV test in the US and Canada.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.

The San Diego Union-Tribune takes a look at the work to be done in personalized medicine.

An op-ed in the Wall Street Journal calls for the establishment of a patent court staffed by judges and experts with science backgrounds.

In PLOS this week: variants that affect COPD biomarkers, high genetic diversity of Cryptococcus gattii in Brazil, and more.